We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma (PICASSO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04988841
Recruitment Status : Recruiting
First Posted : August 4, 2021
Last Update Posted : March 29, 2022
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
Recent studies suggest that patients with metastatic melanoma whose gut microbiome is colonized by eubiotic bacteria have a stronger anti-cancer response to anti CTLA-4 and anti PD1. The hypothesis of this research is that a pooled standardized fecal microbiome transfer (FMT) will shift melanoma patients' gut microbiome towards a composition close to that associated with a better response, and will therefore increase the response to a combination of anti CTLA-4 and anti PD1, without affecting the safety of these drugs. The present trial is the first randomized trial of FMT in patients with unresectable or metastatic melanoma. It will include patients who have neither been exposed to anti CTLA-4 nor anti PD1 or PDL-1, prior to inclusion in the study. The pooled standardized fecal microbiome transfer administered in this study is an experimental drug MaaT013, a microbiome restoration biotherapeutic, produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome. The MaaT013 product has a standardized richness (in number of species present) higher than a product obtained from a mono donor (455 species approximately against 274 on average) and contains bacteria species (mentioned in the rationale) associated with better response to anti- CTLA-4 and anti PD1.

Condition or disease Intervention/treatment Phase
Melanoma Drug: MaaT013 Drug: Ipilimumab Drug: Nivolumab Drug: MoviPrep Drug: Normacol Drug: Placebo of Maat013 Phase 2

Detailed Description:

PICASSO is a prospective, randomized, proof of concept clinical trial. This trial is about assessing the tolerance and clinical benefit of fecal microbiome transfer in patients with melanoma in addition to the usual treatment with immunotherapy combining ipilimumab (CTLA-4 inhibitor) and nivolumab (PD-1 inhibitor).

In the proposed research, we will compare faecal transplantation using MaaT013 to placebo in 60 patients.

Patients not exposed to anti CTLA-4 and anti PD1 or PDL-1 patients before the trial will be randomized to receive either: ipilimumab + nivolumab + MaaT013 (n = 30) or ipilimumab + nivolumab + placebo (n = 30).

The estimated duration of the study is 37 months. Administration of MaaT013 or placebo will be performed every 3 weeks between baseline and week 9 then from week 15 to week 23 every 4 weeks. A total of 7 fecal microbiome transfer will be performed.

Prior to the first administration (the day before) an evacuating enema by (MOVIPREP or equivalent) will be done, For subsequent administrations, an evacuating enema (equivalent to the specialty Normacol®) will be administered rectally before the transplantation of fecal microbiota or the placebo.

Blood and stool samples will be collected as well as biopsies for the purposes of the study.

An evaluation of the patient's condition will be made at week 27, Unblinding will be performed for patients who have progressed. Patients with disease progression who received placebo will be considered for receiving MaaT013, in an open-label basis, concurrently with nivolumab infusions, at week 31, 35, 39, 43 and 47.

. The end-of-follow-up visit for all patients is scheduled for week 51. Patients who met the inclusion criteria, received Ipilimumab+Nivolumab, who consented to have a baseline stool microbiota analysis before starting treatment with ipilimumab + nivolumab. They will form a cohort of 50 patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multi-center, prospective, randomized, double blinded, pilot, proof-of concept, clinical trial
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: At week 27, unblinding will be performed on patients who progressed. For those who received Placebo, Maat 013 will be administrated in open label.
Primary Purpose: Treatment
Official Title: Prospective randomIzed Clinical Trial Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma Treated With CTLA-4 and PD1 Inhibitors
Actual Study Start Date : January 20, 2022
Estimated Primary Completion Date : January 20, 2024
Estimated Study Completion Date : June 1, 2024

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma

Arm Intervention/treatment
Experimental: Fecal microbiotherapy (MaaT013) associated to ipilimumab and nivolumab
Fecal microbiotherapy MaaT013 (actif arm) enemas will be administered by nurses, at the hospital, in the dermatology department in which the patients are treated for their melanoma. Nurses will be trained to administer enemas. The enema will be administered to the patient in the left lateral position with instructions to retain it for at least 20 minutes
Drug: MaaT013
study is an experimental drug , produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome (455 species approximately against 274 on average)
Other Name: fecal microbiotherapy

Drug: Ipilimumab
Anti cytotoxicT-lymphocyte-associated protein 4 ( immunothérapy)

Drug: Nivolumab
AntiPD1 ( immunothérapy)

Drug: MoviPrep
Osmotic laxative solution : patients take a single dose of two liters of Moviprep® or equivalent the night before the first administration of experimental treatment (Fecal microbiota transfer or placebo)
Other Name: Osmotic laxative solution

Drug: Normacol
hypertonic enema solution
Other Name: hypertonic enema solution

Placebo Comparator: fecal microbiotherapy Placebo associated to ipilimumab and nivolumab
Placebo fecal microbiotherapy will be administered by nurses, at the hospital, in the dermatology department in which the patients are treated for their melanoma. Nurses will be trained to administer enemas. The enema will be administered to the patient in the left lateral position with instructions to retain it for at least 20 minutes
Drug: MaaT013
study is an experimental drug , produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome (455 species approximately against 274 on average)
Other Name: fecal microbiotherapy

Drug: Ipilimumab
Anti cytotoxicT-lymphocyte-associated protein 4 ( immunothérapy)

Drug: Nivolumab
AntiPD1 ( immunothérapy)

Drug: MoviPrep
Osmotic laxative solution : patients take a single dose of two liters of Moviprep® or equivalent the night before the first administration of experimental treatment (Fecal microbiota transfer or placebo)
Other Name: Osmotic laxative solution

Drug: Normacol
hypertonic enema solution
Other Name: hypertonic enema solution

Drug: Placebo of Maat013
expérimental drug placebo of MaaT013
Other Name: fecal microbiotherapy placebo




Primary Outcome Measures :
  1. To assess whether the safety of a 23-week treatment with MaaT013, combined with ipilimumab+nivolumab, is different from that of ipilimumab+nivolumab+placebo in patients with melanoma naïve to Ipilimumab and anti-PD1 [ Time Frame: During the 27 weeks of the trial. ]
    Safety will be measured by the occurrence of Grade 3 and grade 4 adverse events (AE), as graded by the CTCAE v 5.0


Secondary Outcome Measures :
  1. To assess whether a 23-week treatment with MaaT013, combined with Ipilimumab and Nivolumab, is more efficient than Ipilimumab and Nivolumab + placebo in patients with melanoma naïve to Ipilimumab and anti PD1. [ Time Frame: During the 27 weeks of the trial. ]
    The best overall response rate, rated by immunological Response Evaluation Criteria in Solid Tumors (iRECIST; 19) in the experimental and control arms and among them, within the subgroup of patients who carried the unfavourable baseline microbiota.

  2. To assess changes in the tumor microenvironment in patients who have received MaaT013 and placebo ; [ Time Frame: During the 27 weeks of the trial. ]
    Changes in the tumor micro environment (TME) pre and post MaaT013 or placebo

  3. Changes in plasma levels of proteins or metabolites that play a role in immune activity against cancer and/or are associated with gut microbiome composition, pre and post MaaT013 or placebo [ Time Frame: During the 27 weeks of the trial. ]
    Changes in plasma levels of proteins or metabolites that play a role in immune activity against cancer and/or are associated with gut microbiome composition, pre and post MaaT013 or placebo : IL-6, IL-8, MCP1, IL-1β, TNF α, sCD25, sCTLA-4, sPD-L1, short chain fatty acids (SCFA), all in micromol/L

  4. To assess peripheral blood T cell subpopulations that have been identified as associated with gut microbiome composition or response to anti CTLA-4 and anti PD1 in previous human studies; CD244+ T cells, monocytes subpopulations, memory T cells and Tregs [ Time Frame: During the 27 weeks of the trial. ]
    Changes in peripheral blood immune cell subpopulations pre and post MaaT013 or placebo

  5. To assess the evolution of gut microbial members and metabolites; [ Time Frame: During the 27 weeks of the trial. ]

    Microbial composition will be described by 16S ribosomal RNA gene sequencing as follows:

    • Microbial diversity indices (Shannon, Simpson, etc…)
    • Proportions of each bacterial taxa in the microbiome of each volunteer

    Microbial metagenomes will be described by shotgun sequencing as follows:

    • Number of bacterial genes (richness)
    • Proportions of each metagenomic unit (species) in the microbiome of each volunteer
    • Proportions of Kegg Orthology functional categories in the microbiome of each volunteer

    Microbial metabolomes will be described by global metabolomic Liquid Chromatography with tandem mass spectrometry as follows:

    • proportions of metabolites in the microbiome of each volunteer
    • proportions of specific pathways (KEGG) in the microbiome of each volunteer

  6. To assess, on an open basis, the efficacy and safety of MaaT013 combined with Nivolumab in a subset of patients who failed to respond to placebo [ Time Frame: During the 51 weeks of the trial. ]
    Overall response rate, either complete or partial, rated by Response Evaluation Criteria in Solid Tumours in patients with a stable disease or disease progression who received MaaT013, in an open-label basis.

  7. To assess the efficacy and safety of MaaT013 combined with Ipilimumab and Nivolumab in the randomized part of the trial. [ Time Frame: During the 27 weeks of the trial. ]
    Overall response rate, either complete or partial, rated by Response Evaluation Criteria in Solid Tumours in patients with a stable disease or disease progression who received MaaT013, in an open-label basis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged 18 to 80
  • Patients with unresectable or metastatic melanoma
  • Patients with ECOG performance of 0-2
  • Patients able to provide written informed consent and understand the risks associated with MaaT013
  • Have measurable disease as per RECIST version 1.1, on a tumor evaluation (either CT scan, physical evaluation or ultrasonography) performed less than 2 weeks before screening visit
  • Requiring a treatment with Ipilimumab and PD1 inhibitor (Nivolumab) and having no contraindication to these drugs nor to their excipients
  • Patients unexposed to ipilimumab and anti PD1 or anti PDL1 except if they have received it in the adjuvant setting (if the last dose of Ipilimumab® or anti PD1 or anti PDL1 was received at least 6 months before randomization).
  • Negative pregnancy test (serum)
  • Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for the duration of study treatment with nivolumab, ipilimumab and 6 months after the last dose of study treatment (ie, 30 days (duration of ovulatory cycle) plus the time required for the investigational drug to undergo approximately five half-lives)
  • Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of study treatment with nivolumab, ipilimumab and 7 months after the last dose of study treatment {i.e., 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo approximately five half-lives.}
  • Hemoglobin ≥9 g/dL
  • Platelets ≥ 100000mm3
  • Neutrophils ≥ 1500/mm3
  • Creatinine Clearance ≥ 50mL/mn
  • AST ≤ 3N
  • ALT ≤ 3N
  • Total bilirubin ≤ 1.5N (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
  • Alkaline phosphatase ≤ 3N
  • INR < 1.5
  • Prothrombin ≥ 70%
  • TCA < 1.2
  • No Hepatocellular insufficiency

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Antibiotics in the last two weeks prior to the FMT
  • Inability to retain enemas
  • Expected to require any other form of systemic or localized anti-neoplastic therapy while on study
  • Active infection requiring systemic therapy.
  • Active, known or suspected autoimmune disease.
  • No health insurance,
  • Patients already included in a clinical research other than an observational study (e.g: registry, cohort).
  • Patient on AME (state medical aid) (unless exemption from affiliation)
  • Patients guardianship/legal protection/curatorship
  • Contraindication to fecal transplantation
  • Known hypersensitivity to Normacol or Moviprep® or equivalent patent medicines enema or one of their components.
  • Fluid-electrolyte disorders with sodium retention (heart failure, hyperaldosteronism, drug-induced edema)
  • Recent acute coronary syndrome or unstable ischemic heart disease
  • Congestive heart failure ≥ Class III or IV as defined by New York Heart Association
  • Hypersensitivity to the active substances or to any of the excipients: Aspartame (E951), Acesulfame, potassium (E950), lemon flavor (maltodextrin, citral, lemon essential oil, lime essential oil, xanthan gum, vitamin E)
  • Gastrointestinal obstruction or perforation
  • Gastric emptying disorders (gastroparesis),
  • Ileus,
  • Phenylketonuria (due to the presence of aspartame),
  • Deficiency in glucose-6-phosphate dehydrogenase (due to the presence of ascorbate),
  • Toxic megacolon, in severe forms of inflammation of the intestinal tract, including Crohn's disease and ulcerative colitis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04988841


Contacts
Layout table for location contacts
Contact: Franck CF CARBONNEL, Professor + (33) 145213722 Franck.carbonnel@aphp.fr
Contact: Caroline CR ROBERT, Professor + (33) 142114210 Caroline.ROBERT@gustaveroussy.fr

Locations
Layout table for location information
France
Hôpital Nantes Hôtel Dieu Recruiting
Nantes, France, 44000
Contact: Quereux Gaelle, PhD    0240087901    gaelle.quereux@chu-nantes.fr   
Hôpital Saint Louis Recruiting
Paris, France, 75010
Contact: CELESTE LEBBE, PHd    0142499392    celeste.lebbe@aphp.fr   
Hôpital Gustave Roussy Recruiting
Villejuif, France, 94800
Contact: Robert Caroline    0142116497    caroline.robert@gustaveroussy.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT04988841    
Other Study ID Numbers: APHP200133
First Posted: August 4, 2021    Key Record Dates
Last Update Posted: March 29, 2022
Last Verified: March 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Fecal microbiome transfer
Microbiome restoration biotherapeutic
Full-ecosystem intestinal microbiome
Response to anti- CTLA-4 and anti PD1
the tumor microenvironment
Peripheral blood T cell subpopulations
Efficacy and safety of MaaT013
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Nivolumab
Ipilimumab
Laxatives
Pharmaceutical Solutions
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents